Skip to main content
. 2021 Apr 4;73(6):1003–1012. doi: 10.1093/cid/ciab288

Figure 1.

Figure 1.

Risk of hospitalized VCD and severe VCD in the pooled studies (CYD14, CYD15, and CYD23/57) over the 6-year period in those seropositive or seronegative by MI M0, TMLE*, and NS1 M13 (Th9) in participants aged (A) ≥9 years and (B) <9 years. Study group classified as treated (participants included in the CYD-TDV group if they received at least one injection of CYD-TDV vaccine). n represents the number of subjects fulfilling the item listed; N represents the total number of subjects selected in subcohort. NS1 M13 (Th9), dengue anti-nonstructural protein-1 (NS1) IgG ELISA at M13 with seropositivity defined as ≥9 EU/mL (threshold 9). For all MI approaches n and N are average numbers from 10 iterations of multiple imputations. For NS1 M13 (Th9) participants with VCD cases before M13 were excluded from the analyses. *TMLE data presented as relative risk (95% CI), N divided by 10; pooled TMLE data for CYD14 and CYD15. Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; MI, multiple imputation; M0, baseline; TMLE, targeted minimum loss-based estimation; VCD, virologically confirmed dengue.